Interaction Between PPARγ2 Variants and Gender on the Modulation of Body Weight

[1]  Nazim Madhavji,et al.  Organization , 2020, WER.

[2]  M. Hutz,et al.  Effects of a PPARG gene variant on obesity characteristics in Brazil. , 2007, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[3]  N. Abate,et al.  The Q121/Q121 Genotype of ENPP1/PC‐1 Is Associated with Lower BMI in Non‐diabetic Whites , 2007, Obesity.

[4]  M. Stumvoll,et al.  Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. , 2006, Diabetes care.

[5]  Karine Clément,et al.  Genetics of human obesity. , 2006, The Proceedings of the Nutrition Society.

[6]  M. Abney,et al.  The sex-specific genetic architecture of quantitative traits in humans , 2006, Nature Genetics.

[7]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[8]  R. Vigneri,et al.  Evidence for genetic epistasis in human insulin resistance: the combined effect of PC-1 (K121Q) and PPARγ2 (P12A) polymorphisms , 2003, Journal of Molecular Medicine.

[9]  M. Laakso,et al.  Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. , 2002, European journal of endocrinology.

[10]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[11]  B. Spiegelman,et al.  PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.

[12]  J. Beilby,et al.  A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. , 2001, European journal of endocrinology.

[13]  A. Astrup,et al.  Obesity : Preventing and managing the global epidemic , 2000 .

[14]  Young-Bum Kim,et al.  Increased Energy Expenditure, Decreased Adiposity, and Tissue-Specific Insulin Sensitivity in Protein-Tyrosine Phosphatase 1B-Deficient Mice , 2000, Molecular and Cellular Biology.

[15]  J. Auwerx,et al.  Impact of the Peroxisome Proliferator Activated Receptor γ2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus , 2000, International Journal of Obesity.

[16]  M. Laakso,et al.  Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. , 1999, The Journal of clinical endocrinology and metabolism.

[17]  H. Münzberg,et al.  Missense variants in the human peroxisome proliferator-activated receptor-gamma2 gene in lean and obese subjects. , 1999, European journal of endocrinology.

[18]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[19]  C. Yen,et al.  Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. , 1998, Diabetes.

[20]  Y. Yazaki,et al.  Effect of the Pro12Ala variant of the human peroxisome proliferator-activated receptor gamma 2 gene on adiposity, fat distribution, and insulin sensitivity in Japanese men. , 1998, Biochemical and biophysical research communications.

[21]  L. Peltonen,et al.  Dual origins of Finns revealed by Y chromosome haplotype variation. , 1998, American journal of human genetics.

[22]  J. Auwerx,et al.  A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. , 1998, Human molecular genetics.

[23]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[24]  B. Spiegelman,et al.  PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. , 2001, The Journal of biological chemistry.

[25]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[26]  Who Consultation on Obesity.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation. , 2000, World Health Organization technical report series.